Berita Valas

Swiss Market Ends Slightly Up

The Switzerland market ended slightly up on Wednesday after a choppy session with investors largely refraining from making significant moves amid a lack of fresh triggers.
RTTNews | 994 hari yang lalu
European Stocks Close On Weak Note

European Stocks Close On Weak Note

European stocks closed lower on Wednesday amid worries about economic slowdown in the region and a bit of uncertainty about the outlook for Federal Reserve's interest-rate trajectory ahead of inflation data.
RTTNews | 994 hari yang lalu
Pound Advances Against Most Majors

Pound Advances Against Most Majors

The pound was higher against its most major counterparts in the New York session on Wednesday, as investors awaited key inflation reports to help determine the Fed's policy path.
RTTNews | 994 hari yang lalu
U.S. Wholesale Inventories Dip In Line With Estimates In November

U.S. Wholesale Inventories Dip In Line With Estimates In November

Wholesale inventories in the U.S. dipped in line with economist estimates in the month of November, according to a report released by the Commerce Department on Wednesday. The Commerce Department said wholesale inventories edged down by 0.2 percent in November after falling by a revised 0.3 percent in October.
RTTNews | 994 hari yang lalu
Berita lainnya
Masimo Boosts FY23 Adj. EPS Outlook

Masimo Boosts FY23 Adj. EPS Outlook

Technology company Masimo Corp. (MASI) announced Wednesday select preliminary financial results for the fourth quarter and full-year ended December 30, 2023 and provided estimates for its full-year 2024 guidance.
RTTNews | 994 hari yang lalu
Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference later on Wednesday, Ginkgo Bioworks (DNA) said it expects to meet its previously disclosed new program and revenue guidance ranges in 2023, based on its preliminary unaudited estimates.
RTTNews | 994 hari yang lalu
Clearmind Medicine Says It Completed Type A Meeting With FDA; Stock Up 38%

Clearmind Medicine Says It Completed Type A Meeting With FDA; Stock Up 38%

Biotech company Clearmind Medicine, Inc. (CMND) announced Wednesday it has completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company's clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of Alcohol Use Disorder treatment (AUD) using its novel psychedelic- based therapy.
RTTNews | 994 hari yang lalu
Bay Street Seen Opening On Mixed Note

Bay Street Seen Opening On Mixed Note

Canadian shares look headed for a mixed start on Wednesday, tracking global cues and slightly higher commodity prices. Ahead of crucial inflation data from the U.S., and earnings updates from major banks, the mood is likely to remain cautious.
RTTNews | 994 hari yang lalu

Tetap ikuti informasi terbaru!

Tambahkan Berita ke browser Anda

Extension Picture